Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015 Print E-mail
Tuesday, 24 February 2015 22:20
KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.
Read more...
 
Provectus Biopharmaceuticals Will Present at 8th Annual European Life Science CEO Forum & Exhibition Print E-mail
Wednesday, 18 February 2015 19:39
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will present at the 8th Annual European Life Science CEO Forum & Exhibition. Peter Culpepper, CFO and COO, will present on March 3, 2015, at 3:15 pm local time.
Read more...
 
Significant Findings in U.S. National Institutes of Health's Trial of Pluristem's PLX-R18 Cells for Treatment of Acute Radiation Syndrome Print E-mail
Wednesday, 18 February 2015 08:50
HAIFA, Israel--Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today the positive results of a recently completed trial conducted by the U.S. National Institutes of Health (NIH) to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster.
Read more...
 
Late Melanoma Patients Will Need Several Lines of Therapy, Intralesional Treatment Promising Says New Paper Print E-mail
Thursday, 12 February 2015 16:31
Newswise –February 12, 2015- Despite advances in melanoma treatment, many patients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma will need several lines of therapy according to a recent paper in Current Opinion in Oncology.
Read more...
 
The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial Print E-mail
Wednesday, 11 February 2015 20:14
VIENNA, Va.--CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Philippines Regulatory Agency (PFDA) has cleared the Company to commence patient enrollment of the Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the Philippines.
Read more...
 
TapImmune's CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" for Phase II Trials Print E-mail
Tuesday, 10 February 2015 12:54
TapImmune Inc. (OTCQB: TPIV), the emerging clinical-stage immunotherapy company which develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases has been grabbing the attention of biotech investors as they ready multiple products for Phase II Clinical Trials.
Read more...
 
ACTINIUM ENGAGES DR. ROLAND TURCK FORMER PRESIDENT, GLOBAL SPECIALTY MEDICINE, BAYER HEALTHCARE AS BOARD ADVISOR Print E-mail
Wednesday, 04 February 2015 10:45
New York, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it engaged Dr. Roland Turck, Managing Partner at TurckBio, as a senior advisor to the Board of Directors.
Read more...
 
FDA Issues Import Block On Eli Lilly's Cialis; Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact Print E-mail
Tuesday, 13 January 2015 20:00
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 13, 2015.
Read more...
 
AAA Fully Acquires Atreus Pharmaceuticals; Enrolls First Patient In A Phase I/II Clinical Trial For Its Key Diagnostic Candidate Annexin V-128 In Rheumatoid Arthritis And Ankylosing Spondylitis Print E-mail
Friday, 09 January 2015 08:13
08 January 2015 – Advanced Accelerator Applications S.A. (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), announced today that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada and
focused on the development of proprietary molecular imaging products aimed at imaging apoptosis and

Error. Page cannot be displayed. Please contact your service provider for more details. (1)

necrosis based on Annexin V. Atreus Pharmaceuticals Corporation is now a fully owned AAA subsidiary and
has been renamed AAA Canada.
Read more...
 
Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment Print E-mail
Tuesday, 23 December 2014 01:02
KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will be meeting with the U.S. Food and Drug Administration (the “FDA”) to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 12
BMR:1